Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Trial of TransCon PTH in Adults with Hypoparathyroidism
2018-004815-33Phase 2Active
- Sponsor
- Ascendis Pharma
- Start
- Mar 2019
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of palopegteriparatide in hypoparathyroidism (4 arms), sponsored by Ascendis Pharma. Primary endpoints: Primary effectiveness of TransCon PTH on calcium homeostasis at 4 weeks and Safety and tolerability of daily TransCon PTH. Started Mar 2019; status: active.
02
Drugs
palopegteriparatide
03
Conditions
hypoparathyroidism
Beyond the preview
Go deeper on 2018-004815-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004815-33.